Mark Geng

Mark is the director, gRNA process development at Verve Therapeutics. Prior to joining Verve, Mark was a principal scientist and a team lead at Moderna, where he led the process development of mRNA-based vaccine and therapeutic products. Prior to that, he was a senior and later a principal scientist at Bristol-Myers Squibb. He was leading several end-to-end process intensifications and helped solving facility fit challenges for protein and viral vector therapies. He also worked at Merck MilliporeSigma as a GLP study director for IND enabling studies and a downstream purification technical leader.